Check the time stamp on this data. Updated AI-Generated Signals for Novavax Inc. (NVAX) available here: NVAX.

NVAX's COVID-19-flu combination and stand-alone flu vaccines have been placed on hold after a study participant who took the ...

Analyst Eric Joseph of J.P. Morgan maintained a Sell rating on Novavax (NVAX – Research Report), retaining the price target of $9.00.

On Wednesday, Novavax Inc (NVAX) stock saw a decline, ending the day at $10.15 which represents a decrease of $-2.45 or -19.44% from the prior close of $12.6. The stock opened at $10.43 and touched a ...

Highlights,Novavax faces a clinical hold following the report of motor neuropathy in a trial participant nearly two years ...

Novavax Inc. (NASDAQ:NVAX) stock is trading lower on Wednesday. The FDA has placed a clinical hold on Novavax’s ...

The U.S. Food and Drug Administration has put Novavax's trial of an experimental COVID-flu vaccine combination on hold after ...

Shares of American pharmaceutical company Novavax (NVAX) fell 19% on reports that the U.S. Food and Drug Administration (FDA) ...

On Wednesday, major U.S. indices saw gains, with the Dow Jones Industrial Average climbing nearly 0.8% to 43,077.70.

Shares of pharmaceutical company Novavax ($NVAX) are down 18% on news that the U.S. Food and Drug Administration (FDA) has ...

Shares of US protein-based vaccine maker Novavax closed down 19.4% at $10.15 yesterday having dropped as much as 24%, on the ...

Flu season is almost here, and there is a respiratory syncytial virus (RSV) vaccine update worth monitoring. Earlier today, ...